GlassScriptPhysician profile
Susan Boyle
NPI 1871507418
$641.20
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $105 · 2022: $18.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $81.59 | 2019 | |
| Novo Nordisk INC | $61.47 | 2019 | |
| Corcept Therapeutics | $60.75 | 2019-2020 | |
| Concordia Pharmaceuticals INC. | $53.14 | 2019 | |
| Lilly USA, LLC | $50.56 | 2019 | |
| Astellas Pharma US INC | $49.55 | 2019-2020 | |
| Pfizer INC. | $46.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.81 | 2019 | |
| Glaxosmithkline, LLC. | $40.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $32.71 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $27.59 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $25.82 | 2019 | |
| Abbvie INC. | $21.15 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.44 | 2019 | |
| Irhythm Technologies, INC. | $16.85 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $13.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.